COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
16 hedge funds and large institutions have $591K invested in COSCIENS Biopharma Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
28% less capital invested
Capital invested by funds: $824K → $591K (-$233K)
31% less call options, than puts
Call options by funds: $27K | Put options by funds: $39K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$109K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$107K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20K |
| 4 |
JP Morgan Chase
New York
|
+$10.2K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$5.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$80K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$39K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$33.1K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$13.7K |
CSCI Hedge Fund Activity: Q1 2018 in Review
16 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2018, worth a combined $591K — down 28% from $824K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CSCI positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $109K. The largest seller was Brandes Investment Partners, exiting entirely with an estimated $80K sold.
- 16 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2018, up from 15 in Q4 2017.
- Funds reported $591K of COSCIENS Biopharma Inc. Common Stock stock for Q1 2018, down 28% quarter-over-quarter.
- 3 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2018 and 2 closed out, a net change of +1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2018 was Morgan Stanley, an estimated $109K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2018 was Brandes Investment Partners, an estimated $80K sold.
Based on aggregated 13F filings for Q1 2018.